occurred in people aged 16 years or older. 8472 (60%) of Leumit PCR tests used TaqPath during the study period, of which 8006 had an SGTF, giving an estimated prevalence of 94·5% for the B.1.1.7 variant. As of April 3, 2021, BNT162b2 was the only COVID-19 vaccine available in Israel, and more than 10∙0 million doses were administered to more than 5∙2 million people. Overall, 4 714932 (72∙1%) of 6538911 people aged 16 years or older and 1015620 (90∙0%) of 1 127965 people aged 65 years or older were fully vaccinated with two doses (table 1). By sector, among those aged 16 years or older, 669542 (54∙6%) of 1226788 in the Arab population, 228479 (42∙8%) of 534 146 in the ultra-Orthodox population, and 3816911 (79∙9%) of 4 777977 in the general Jewish population were fully vaccinated with two doses. Median follow-up for people who received two doses was 48 days (IQR 30–60). Among 154 648 SARS-CoV-2 infections in those aged 16 years and older, 109876 (71∙0%) were unvaccinated and 6266 (4∙1%) were fully vaccinated (with ≥7 days after the second dose). Among 54 677 people aged 16 years and older who had symptomatic COVID-19, 39 065 (71∙4%) were unvaccinated and 1692 (3∙1%) received two doses (with ≥7 days after the second dose). Among 7694 people aged 16 years and older who were hospitalised with COVID-19, 5526 (71∙8%) were unvaccinated and
SARS-CoV-2 infection¶ Age 16–44 years 84611 95∙1 1801 2∙3 95∙4% (94∙0–96∙5) 96∙1% (95∙7–96∙5) Age 45–64 years 19579 86∙1 2264 3∙4 93∙6% (91∙4–95∙3) 94∙9% (94∙2–95∙5) Age ≥65 years 5686 67∙7 2201 3∙8 93∙4% (91∙3–95∙0) 94∙8% (93∙9–95∙5) All ages 109876 91∙5 6266 3∙1 94∙2% (93∙2–95∙1) 95∙3% (94∙9–95∙7) Asymptomatic SARS-CoV-2 infection Age 16–44 years 40088 45∙1 1174 1∙5 92∙8% (90∙3–94∙7) 93∙6% (92∙8–94∙4) Age 45–64 years 7414 32∙6 1343 2∙0 89∙1% (84∙7–92∙3) 90∙8% (89∙6–91∙9) Age ≥65 years 1636 19∙5 1115 1∙9 85∙9% (80∙2–89∙9) 88∙5% (86∙4–90∙3) All ages 49138 40∙9 3632 1∙8 90∙1% (88∙0–91∙8) 91∙5% (90∙7–92∙2) Symptomatic COVID-19 Age 16–44 years 28196 31∙7 352 0∙5 97∙8% (97∙0–98∙3) 97∙6% (97∙3–97∙8) Age 45–64 years 7790 34∙3 560 0∙8 96∙3% (95∙0–97∙3) 96∙7% (96∙3–97∙0) Age ≥65 years 3079 36∙6 780 1∙4 96∙1% (94∙8–97∙1) 96∙4% (95∙9–97∙0) All ages 39065 32∙5 1692 0∙8 96∙6% (95∙8–97∙2) 97∙0% (96∙7–97∙2) COVID-19-related hospitalisation Age 16–44 years 2043 2∙3 33 <0∙1 98∙1% (97∙1–98∙8) 98∙1% (97∙3–98∙7) Age 45–64 years 1687 7∙4 112 0∙2 97∙6% (96∙9–98∙2) 97∙6% (97∙1–98∙1) Age ≥65 years 1826 21∙7 451 0∙8 96∙6% (95∙3–97∙6) 96∙8% (96∙2–97∙3) All ages 5526 4∙6 596 0∙3 96∙7% (95∙5–97∙6) 97∙2% (96∙8–97∙5) Severe or critical COVID-19-related hospitalisation Age 16–44 years 644 0∙7 7 0∙01 98∙8% (97∙3–99∙5) 98∙9% (97∙6–99∙5) Age 45–64 years 1132 5∙0 62 0∙1 98∙1% (97∙2–98∙6) 98∙1% (97∙5–98∙5) Age ≥65 years 1425 17∙0 295 0∙5 97∙2% (95∙9–98∙1) 97∙3% (96∙8–97∙8) All ages 3201 2∙7 364 0∙2 97∙2% (95∙9–98∙1) 97∙5% (97∙1–97∙8) COVID-19-related death Age 16–44 years 36 0∙04 0 0∙0 100 100 Age 45–64 years 125 0∙5 14 <0∙1 96∙2% (92∙6–98∙0) 95∙8% (92∙6–97∙6) Age ≥65 years 554 6∙6 124 0∙2 96∙8% (94∙6–98∙1) 96∙9% (96∙0–97∙6) All ages 715 0∙6 138 0∙1 96∙6% (93∙9–98∙1) 96∙7% (96∙0–97∙3) Numbers and incidence rates of outcomes are shown for unvaccinated and fully vaccinated individuals. Vaccine effectiveness estimates are % (95% CI). *Defined as people for whom at least 7 days had passed after the second dose of BNT162b2 vaccine. †Total person-days for all outcomes were 88938310 for age 16–44 years, 22734104 for age 45–64 years, 8403722 for age ≥65 years, and 120076136 for all ages. ‡Total person-days for all outcomes were 77280829 for age 16–44 years, 67027668 for age 45–64 years, 57573686 for age ≥65 years, and 201882183 for all ages. §Model is adjusted for age group (16–24, 25–34, 35–44, 45–54, 55–64, 65–74, 75–84, and ≥85 years), sex, and calendar week. ¶Includes asymptomatic and symptomatic infections, as well as cases with positive SARS-CoV-2 tests for which the symptom interview portion of the epidemiological investigation was not completed. Table 2: Estimated effectiveness of two doses of BNT162b2 (≥7 days after the second dose) against laboratory-confirmed SARS-CoV-2 outcomes by age
